as 05-09-2025 2:37pm EST
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
Founded: | 2019 | Country: | United States |
Employees: | N/A | City: | PHILADELPHIA |
Market Cap: | 58.1M | IPO Year: | 2021 |
Target Price: | $3.67 | AVG Volume (30 days): | 725.0K |
Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.61 | EPS Growth: | N/A |
52 Week Low/High: | $0.34 - $3.47 | Next Earning Date: | 05-20-2025 |
Revenue: | $6,589,000 | Revenue Growth: | 194.81% |
Revenue Growth (this year): | 833.1% | Revenue Growth (next year): | -86.94% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Carr Douglas | IPSC | SVP Finance & Operations | May 5 '25 | Sell | $0.55 | 295 | $162.25 | 410,886 | |
Farid Adrienne | IPSC | Chief Operations Officer | Mar 10 '25 | Sell | $0.62 | 2,359 | $1,450.79 | 131,717 | |
Pfeiffenberger Brent | IPSC | President and CEO | Mar 10 '25 | Sell | $0.62 | 2,235 | $1,374.53 | 1,190,310 | |
Russotti Gregory | IPSC | See Remarks | Mar 10 '25 | Sell | $0.62 | 2,360 | $1,451.40 | 272,573 | |
Carr Douglas | IPSC | SVP Finance & Operations | Mar 10 '25 | Sell | $0.62 | 1,240 | $762.60 | 410,886 | |
Pfeiffenberger Brent | IPSC | President and CEO | Feb 18 '25 | Sell | $0.78 | 34,712 | $27,179.50 | 1,190,310 |
IPSC Breaking Stock News: Dive into IPSC Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
GlobeNewswire
11 days ago
GlobeNewswire
24 days ago
Zacks
a month ago
MT Newswires
2 months ago
Simply Wall St.
2 months ago
MT Newswires
2 months ago
Zacks
2 months ago
The information presented on this page, "IPSC Century Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.